

Pavel Drevinek

My professional career is closely linked to cystic fibrosis. As a PhD student, I entered the field of CF when an outbreak of *Burkholderia cenocepacia* infection at our CF centre needed to be investigated. We described the new *Burkholderia* clone and beat the epidemic, but CF pathogens including *Burkholderia* remained my major interest for laboratory research until today.

In 2012, the Prague CF centre joined the ECFS Clinical Trials Network (CTN) and I was honoured to become a member of the CTN executive committee (EC). Thanks to this, I expanded my knowledge of CF well beyond the area of CF microbiology: as a principal investigator for the Prague CF centre, I got strongly involved in clinical studies and also gained valuable experience from the EC CTN. In 2016, I was appointed leader of the Standards of Care ECFS Working Group for a period of 3 years, during which I tried to raise the issues of Eastern Europe and disparities in CF care across the continent. This is being done in close collaboration with ECFS and CF Europe. My ambition is to carry on in these activities and represent a voice of Eastern Europe in the Board.